Format

Send to

Choose Destination
Blood. 2003 Aug 15;102(4):1529-30. Epub 2003 Apr 17.

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.

Author information

1
Service d'Hématologie, Hôpital Franz Fanon, Blida, Algeria.

Abstract

Hydroxyurea (HU) enhances fetal hemoglobin (Hb) production. An increase in total Hb level has been repeatedly reported during HU treatment in patients with sickle cell disease and in several patients with beta-thalassemia intermedia. Effects in patients with beta-thalassemia major are controversial. We now report a marked elevation of total Hb levels with HU that permitted regular transfusions to be stopped in 7 children with transfusion-dependent beta-thalassemia. The median follow-up was 19 +/- 3 months (range, 13-21 months). We conclude that HU can eliminate transfusional needs in children with beta-thalassemia major, which could be particularly useful in countries such as Algeria, where supplies of blood or chelating agents are limited.

PMID:
12702505
DOI:
10.1182/blood-2003-01-0117
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center